Stock DMAC DIAMEDICA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Delayed Nasdaq
Other stock markets
 02:48:08 2024-05-01 pm EDT 		5-day change 1st Jan Change
2.594 USD +2.51% Intraday chart for DiaMedica Therapeutics Inc. +5.86% -8.68%
Apr. 17 DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment MT
Apr. 17 DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke CI

Evolution of the average Target Price on DiaMedica Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

d86d44a5b7964b946dfecd3.1jXJjJ6GtiCvCJTHOH4zgkJvbgI1u1vjEe4-XI_MuIE.5FD_5cbz2G3BZfCeSEZ26i8eD3V3yHaleplQKqKt8PmUA6rT_-eFaPlG4w~b977d7c8f445500d25e5ce246afb0b0b

Analyst Recommendations on DiaMedica Therapeutics Inc.

Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating MT
Oppenheimer Upgrades DiaMedica Therapeutics to Outperform From Perform, $7 Price Target MT
Oppenheimer Downgrades DiaMedica Therapeutics to Market Perform From Outperform MT
Lake Street Trims DiaMedica Therapeutics' Price Target to $8 From $14, Keeps Buy Rating MT
Craig Hallum Lowers DiaMedica Therapeutics' Price Target to $12 From $18, Keeps Buy Rating MT
Roth Lowers Price Target for DiaMedica Therapeutics to $16 From $24, Maintains Buy Rating MT
Oppenheimer Adjusts DiaMedica Therapeutics' Price Target to $15 From $17, Maintains Outperform Rating MT
Maxim Group Adjusts DiaMedica Therapeutics Price Target to $6 From $11, Maintains Buy Rating MT
Oppenheimer Adjusts DiaMedica Therapeutics PT to $17 From $21, Maintains Outperform Rating MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics PT to $24 From $32, Maintains Buy Rating MT
DIAMEDICA THERAPEUTICS : Maxim Group Adjusts Price Target on DiaMedica Therapeutics to $11 From $14, Reiterates Buy Rating MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics' Price Target to $32 From $38, Maintains Buy Rating MT
DIAMEDICA THERAPEUTICS : Oppenheimer Starts DiaMedica Therapeutics at Outperform With $27 Price Target MT
DIAMEDICA THERAPEUTICS : Craig-Hallum Adjusts Price Target on DiaMedica Therapeutics to $20 From $15, Maintains Buy Rating MT
DIAMEDICA THERAPEUTICS : Roth Capital Initiates Coverage on DiaMedica Therapeutics at Buy, Sets Price Target at $38 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.53 USD
Average target price
7 USD
Spread / Average Target
+176.68%
High Price Target
8 USD
Spread / Highest target
+216.21%
Low Price Target
6 USD
Spread / Lowest Target
+137.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering DiaMedica Therapeutics Inc.

Oppenheimer
Craig-Hallum
Lake Street
Roth Capital Partners
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DMAC Stock
  4. Consensus DiaMedica Therapeutics Inc.